Welcome to our dedicated page for Quidel news (Ticker: QDEL), a resource for investors and traders seeking the latest updates and insights on Quidel stock.
QuidelOrtho Corporation reports developments in in vitro diagnostics, including rapid testing, immunoassay and molecular testing, clinical chemistry, transfusion medicine and point-of-care diagnostic platforms. Company updates commonly address financial results, revenue trends, guidance, respiratory testing seasonality, international market conditions and portfolio activity across labs, cardiac, immunohematology and molecular diagnostics.
Recurring news also covers product and technology developments such as the LEX VELO System, a point-of-care molecular PCR platform with FDA 510(k) clearance and CLIA waived status for Flu A, Flu B and COVID-19 testing, as well as diagnostic education topics including syphilis screening and high-sensitivity troponin. Governance and management changes appear alongside business updates and investor conference participation.
QuidelOrtho (Nasdaq: QDEL) released Episode 52 of its Science Bytes podcast on October 23, 2025, titled "The Power of Informatics in Clinical Decision-Making." The episode features George Wierschem, Senior Global Product Manager – Informatics, who draws on over 30 years of laboratory experience to explain how informatics platforms connect instruments, data systems and clinical decisions.
Key takeaways include:
- Instant insight: turning data into decisions
- Smarter workflows: automation reduces errors and speeds results
- Point-of-care confidence: quality across decentralized testing
- Built-in security: cyber-safe systems without slowing operations
- Trustworthy data: full tracking and accountability
The episode highlights informatics' role in improving lab efficiency, data integrity and patient care. The podcast is available on major streaming platforms and at the company website.
QuidelOrtho (Nasdaq: QDEL) will report its Third Quarter 2025 financial results for the period ended September 28, 2025 after market close on Wednesday, November 5, 2025.
The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss results, with presentation materials posted to the Events & Presentations section of the investor relations website at the time of the call.
Live access: webcast via https://ir.quidelortho.com; phone dial-in: 833-470-1428 (US) or +1 929-526-1599 (international) using Conference ID 415850. A replay will be available on the investor relations site shortly after the event.
QuidelOrtho (Nasdaq: QDEL) will highlight its transfusion medicine portfolio at the AABB 2025 Annual Meeting on Oct 16–17, 2025, following the FDA approval of the MTS™ DAT Card.
The MTS DAT Card completes the company's gel-based direct antiglobulin testing solution and, when paired with the ORTHO VISION™ Platform, offers column agglutination technology with software features like reflex testing and as-needed quality control to speed and standardize transfusion decisions.
Planned activities include education sessions on Rh(D) antigen and DARA interference, poster data on IgG/C3 detection and instrumentation reliability, and product demos of ORTHO VISION Max Swift, ORTHO VISION Swift (noting 98% uptime), and ORTHO CONNECT lab management software.
QuidelOrtho (NASDAQ: QDEL) has released Episode 51 of its Science Bytes podcast featuring Dr. Terry O'Neil, President and Medical Director of Urgent Care Pros. The episode, titled "Through the Shades of Illness, Testing Brings Clarity," focuses on the importance of diagnostic testing in distinguishing between respiratory illnesses with similar symptoms.
Dr. O'Neil, drawing from over 20 years of emergency and urgent care experience, emphasizes how conditions like strep, flu, RSV, and COVID-19 can present similar symptoms, making accurate testing crucial for proper treatment and community health protection. The podcast highlights urgent care centers' vital role in providing immediate access to testing and treatment during respiratory season.
QuidelOrtho (NASDAQ: QDEL) has launched the QUICKVUE Influenza + SARS Test, a professional-use diagnostic tool that simultaneously detects and differentiates between influenza A, influenza B, and SARS-CoV-2 antigens from a single patient sample. The CLIA-waived, 510(k)-cleared test delivers results in as fast as 10 minutes.
The test is designed for use in physician office laboratories, urgent care centers, emergency departments, pharmacies, and decentralized hospital labs. Key features include triple detection capability, fast results, professional use designation, efficient workflow with easy-to-collect nasal swabs, and cost-effective visual combo testing. The product is available in the United States through QuidelOrtho's existing distribution channels but is not intended for in-home use.
QuidelOrtho (NASDAQ: QDEL), a global provider of in vitro diagnostic technologies, announced its participation in the upcoming Baird 2025 Global Healthcare Conference. The company's management team will engage in a fireside chat on September 10, 2025, at 3:10 p.m. ET.
Investors and interested parties can access the live webcast and replay through QuidelOrtho's investor relations website. The company specializes in diagnostic solutions for point-of-care settings, clinical laboratories, and transfusion medicine.
QuidelOrtho (NASDAQ: QDEL) has successfully completed a comprehensive debt refinancing initiative to strengthen its capital structure. The refinancing package includes a $1.15 billion 5-year senior secured Term Loan A, a $100 million delayed draw Term Loan A, a $1.45 billion 7-year senior secured Term Loan B, and a $700 million revolving credit facility.
The restructuring extends debt maturities and reduces required amortization payments, providing enhanced financial flexibility. CFO Joseph Busky emphasized that reducing total debt and net debt leverage remains the company's primary capital allocation priority.
QuidelOrtho (NASDAQ: QDEL) released the 50th episode of its Science Bytes podcast featuring Dr. Jonathan Temte from the University of Wisconsin-Madison discussing respiratory virus prevention in schools. The episode focuses on seasonal health challenges including influenza, RSV, COVID-19, and vaccine-preventable diseases.
Dr. Temte emphasizes three key strategies: early detection through rapid diagnostics for targeted treatment, monitoring absenteeism data to predict outbreaks, and implementing preventive measures to reduce disease transmission in schools and homes. The podcast is available on major streaming platforms and QuidelOrtho's website.
QuidelOrtho (NASDAQ: QDEL) has appointed Erich Wolff as Executive Vice President of Strategy & Corporate Development, reporting to CEO Brian Blaser. Wolff brings over 20 years of leadership experience in healthcare, diagnostics, and MedTech sectors.
Previously serving as Buyouts Lead at Partners Group ($174B AUM), Wolff held senior roles at BD and Medtronic. At Medtronic, he revitalized the global diabetes business and managed corporate development for $11.5B neurosciences and diabetes units. At BD, he led key transactions including the embecta spinoff and $1.5B Parata Systems acquisition.
QuidelOrtho (NYSE:QDEL) has launched its Certified Analyzer Program, aimed at expanding access to diagnostic testing in rural and community hospitals across the United States. The initiative focuses on healthcare facilities with fewer than 100 beds, offering certified VITROS™ analyzers at reduced costs.
The program features certified VITROS XT 7600, 5600 Integrated Systems, and VITROS 3600 Immunodiagnostic System. Each analyzer undergoes a rigorous certification process including over 140 system checks, hardware maintenance, and performance testing at QuidelOrtho's Rochester facility. The certified analyzers come with a 12-month warranty on service and support.